A detailed history of Sequoia Financial Advisors, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Sequoia Financial Advisors, LLC holds 101,679 shares of BMY stock, worth $5.41 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
101,679
Previous 119,293 14.77%
Holding current value
$5.41 Million
Previous $6.47 Million 34.73%
% of portfolio
0.05%
Previous 0.08%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 15, 2024

SELL
$40.25 - $52.99 $708,963 - $933,365
-17,614 Reduced 14.77%
101,679 $4.22 Million
Q1 2024

Apr 30, 2024

BUY
$47.98 - $54.4 $2.03 Million - $2.3 Million
42,244 Added 54.83%
119,293 $6.47 Million
Q4 2023

Jan 25, 2024

BUY
$48.48 - $57.85 $2.05 Million - $2.45 Million
42,301 Added 121.74%
77,049 $3.95 Million
Q3 2023

Nov 08, 2023

SELL
$57.89 - $64.73 $34,097 - $38,125
-589 Reduced 1.67%
34,748 $2.02 Million
Q2 2023

Aug 08, 2023

BUY
$63.71 - $70.74 $119,137 - $132,283
1,870 Added 5.59%
35,337 $2.26 Million
Q1 2023

Apr 24, 2023

BUY
$65.71 - $74.53 $95,542 - $108,366
1,454 Added 4.54%
33,467 $2.32 Million
Q4 2022

Feb 10, 2023

SELL
$68.48 - $81.09 $93,132 - $110,282
-1,360 Reduced 4.08%
32,013 $2.3 Million
Q4 2022

Jan 17, 2023

BUY
$68.48 - $81.09 $873,873 - $1.03 Million
12,761 Added 61.91%
33,373 $0
Q3 2022

Oct 26, 2022

SELL
$0.13 - $76.84 $231 - $136,775
-1,780 Reduced 7.95%
20,612 $1.47 Million
Q2 2022

Jul 22, 2022

SELL
$72.62 - $79.98 $213,938 - $235,621
-2,946 Reduced 11.63%
22,392 $1.72 Million
Q1 2022

May 13, 2022

BUY
$61.48 - $73.72 $350,681 - $420,498
5,704 Added 29.05%
25,338 $1.85 Million
Q4 2021

Feb 11, 2022

BUY
$53.63 - $62.52 $780,316 - $909,666
14,550 Added 286.19%
19,634 $1.22 Million
Q3 2021

Oct 26, 2021

SELL
$59.17 - $69.31 $945,299 - $1.11 Million
-15,976 Reduced 75.86%
5,084 $301,000
Q2 2021

Jul 27, 2021

BUY
$61.91 - $67.42 $167,095 - $181,966
2,699 Added 14.7%
21,060 $1.41 Million
Q1 2021

May 14, 2021

BUY
$59.34 - $66.74 $61,594 - $69,276
1,038 Added 5.99%
18,361 $1.16 Million
Q4 2020

Feb 12, 2021

BUY
$57.74 - $65.43 $47,404 - $53,718
821 Added 4.98%
17,323 $1.08 Million
Q3 2020

Oct 23, 2020

BUY
$57.43 - $63.64 $13,094 - $14,509
228 Added 1.4%
16,502 $995,000
Q2 2020

Aug 25, 2020

BUY
$54.82 - $64.09 $892,140 - $1.04 Million
16,274 New
16,274 $957,000
Q2 2020

Aug 11, 2020

SELL
$54.82 - $64.09 $1.09 Million - $1.27 Million
-19,809 Closed
0 $957,000
Q1 2020

May 11, 2020

SELL
$46.4 - $67.43 $3.13 Million - $4.55 Million
-67,499 Reduced 77.31%
19,809 $1.1 Million
Q4 2019

Feb 13, 2020

BUY
$49.21 - $64.19 $2.63 Million - $3.43 Million
53,511 Added 158.33%
87,308 $5.6 Million
Q3 2019

Oct 22, 2019

BUY
$42.77 - $50.71 $908,563 - $1.08 Million
21,243 Added 169.21%
33,797 $1.71 Million
Q2 2019

Jul 31, 2019

BUY
$44.62 - $49.34 $192,401 - $212,754
4,312 Added 52.32%
12,554 $569,000
Q1 2019

May 13, 2019

SELL
$45.12 - $53.8 $4,872 - $5,810
-108 Reduced 1.29%
8,242 $393,000
Q4 2018

Feb 14, 2019

SELL
$48.76 - $63.23 $1,462 - $1,896
-30 Reduced 0.36%
8,350 $434,000
Q3 2018

Nov 14, 2018

SELL
$55.19 - $62.25 $49,505 - $55,838
-897 Reduced 9.67%
8,380 $520,000
Q2 2018

Aug 14, 2018

BUY
$50.53 - $62.98 $16,877 - $21,035
334 Added 3.73%
9,277 $513,000
Q1 2018

May 14, 2018

BUY
$59.92 - $68.98 $61,238 - $70,497
1,022 Added 12.9%
8,943 $566,000
Q4 2017

Feb 13, 2018

BUY
$59.94 - $65.35 $76,003 - $82,863
1,268 Added 19.06%
7,921 $485,000
Q3 2017

Nov 13, 2017

SELL
$55.23 - $63.74 $43,079 - $49,717
-780 Reduced 10.49%
6,653 $424,000
Q2 2017

Aug 09, 2017

BUY
N/A
7,433
7,433 $414,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Sequoia Financial Advisors, LLC Portfolio

Follow Sequoia Financial Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sequoia Financial Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sequoia Financial Advisors, LLC with notifications on news.